Associations between the genetic polymorphisms of osteopontin promoter and susceptibility to cancer in Chinese population: A meta-analysis

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Liu, Yulan ^a   Lei, Hongbo ^a   Zhang, Jixiang ^a   Wang, Jun ^a   Li, Kui ^a   Dong, Weiguo ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; SPP1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BILE DUCT CARCINOMA; CANCER RISK; CANCER SUSCEPTIBILITY; CHINA; CHINESE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GLIOMA; HUMAN; MOUTH SQUAMOUS CELL CARCINOMA; NASOPHARYNX CARCINOMA; NON SMALL CELL LUNG CANCER; PROMOTER REGION; SPP1 GENE; STOMACH CANCER; THYROID PAPILLARY CARCINOMA; UTERINE CERVIX CANCER; CASE CONTROL STUDY; FEMALE; GENETICS; MALE; META ANALYSIS; NEOPLASM; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; CHINA; FEMALE; HUMANS; MALE; NEOPLASMS; OSTEOPONTIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84942886242     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135318     Document Type: Article

References (40)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108. doi: 10.3322/caac.21262 PMID: 25651787
2. Hudson TJ (2013) Genome variation and personalized cancer medicine. J Intern Med 274: 440-450. doi: 10.1111/joim.12097 PMID: 23751076
3. Stepien E, Wypasek E, Stopyra K, Konieczynska M, Przybylo M, Pasowicz M (2011) Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem 44: 826-831. doi: 10.1016/j.clinbiochem.2011.04.016 PMID: 21539822
4. Kato R, Momiyama Y, Ohmori R, Tanaka N, Taniguchi H, Arakawa K, et al. (2009) Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J 73: 152-157. PMID: 19023151
5. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87. PMID: 16406521
6. Irita J, Okura T, Jotoku M, Nagao T, Enomoto D, Kurata M, et al. (2011) Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am J Physiol Renal Physiol 301: F833-F844. doi: 10.1152/ajprenal.00557.2010 PMID: 21734100
7. Weber GF, Lett GS, Haubein NC (2011) Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep 25: 433-441. doi: 10.3892/or.2010.1106 PMID: 21165579
8. Weber GF, Lett GS, Haubein NC (2010) Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103: 861-869. doi: 10.1038/sj.bjc.6605834 PMID: 20823889
9. Senger DR, Wirth DF, Hynes RO (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16: 885-893. PMID: 88265
10. Wang JL, Nong LG, Tang YJ, Wei YS, Yang FL, Wang CF (2014) Correlation between OPN gene polymorphisms and the risk of nasopharyngeal carcinoma. Med Oncol 31: 20. doi: 10.1007/s12032-014- 0020-x PMID: 24913806
11. Fan Y, Zhang X, Yang ZH, Sun XW, Li SN, Zhong L, et al. (2013) The polymorphisms of osteopontin gene and plasma osteopontin protein levels with susceptibility to colorectal carcinoma. DNA Cell Biol 32: 594-600. doi: 10.1089/dna.2013.2090 PMID: 23952692
12. Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, et al. (2010) The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol 46: 302-306. doi: 10.1016/j.oraloncology.2010.01.018 PMID: 20219412
13. Hijiya N, Setoguchi M, Matsuura K, Higuchi Y, Akizuki S, Yamamoto S (1994) Cloning and characterization of the human osteopontin gene and its promoter. Biochem J 303 (Pt 1): 255-262. PMID: 7945249
14. Dudemaine PL, Thibault C, Alain K, Bissonnette N (2014) Genetic variations in the SPP1 promoter affect gene expression and the level of osteopontin secretion into bovine milk. Anim Genet 45: 629-640. doi: 10.1111/age.12176 PMID: 24961487
15. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25: 603-605. doi: 10.1007/s10654-010- 9491-z PMID: 20652370
16. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. PMID: 12111919
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. PMID: 12958120
18. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. PMID: 3802833
19. Mantel N, HaenszelW(1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748. PMID: 13655060
20. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101. PMID: 7786990
21. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. PMID: 9310563
22. Chen J, Wu Q, Lu Y, Xu T, Huang Y, Ribas J, et al. (2010) SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J Hum Genet 55: 456-461. doi: 10.1038/jhg.2010.48 PMID: 20505679
23. Chen Y, Liu H, Wu W, Li Y, Li J (2013) Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res 32: 45. doi: 10.1186/1756-9966-32-45 PMID: 23883434
24. Lee TY, Lin JT, Wu CC, Yu CC, Wu MS, Lee TC, et al. (2013) Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer. J Clin Gastroenterol 47: e55-e59. PMID: 23426449
25. Mu G, Wang H, Cai Z, Ji H (2013) OPN -443C>T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort. Cell Physiol Biochem 32: 171-179. doi: 10.1159/000350133 PMID: 23867349
26. Shen Z, Chen B, Hou X, Chen P, Zhao G, Fan J (2014) Polymorphism -433 C>T of the Osteopontin gene is associated with the susceptibility to develop gliomas and their prognosis in a Chinese cohort. Cell Physiol Biochem 34: 1190-1198. doi: 10.1159/000366331 PMID: 25277531
27. Xu Q, Yuan B, Xue F, Zhang L, Li J, Guo H, et al. (2011) OPN gene polymorphisms are associated with susceptibility and clinicopatholigical characteristics of cervical cancer in a Chinese cohort. Cancer Biomark 10: 233-239. doi: 10.3233/CBM-2012-0251 PMID: 22699784
28. Zhang R, Yang W, Li YC, Zhang GJ, Yao K, Hu R, et al. (2015) The OPN gene polymorphism confers the susceptibility and response to Ara-C based chemotherapy in Chinese AML patients. Cell Physiol Biochem 35: 175-183. doi: 10.1159/000369685 PMID: 25591760
29. Zhao F, Chen X, Meng T, Hao B, Zhang Z, Zhang G (2012) Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer 12: 477. doi: 10.1186/1471-2407-12-477 PMID: 23072570
30. Zhao XQ, Ma HX, Su MS, He L (2014) Osteopontin promoter polymorphisms at locus -443 are associated with metastasis and poor prognosis of human intrahepatic cholangiocarcinoma in Chinese population. Int J Clin Exp Pathol 7: 6914-6921. PMID: 25400775
31. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, et al. (2008) Osteopontin-c is a selective marker of breast cancer. Int J Cancer 122: 889-897. PMID: 17960616
32. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, et al. (2007) Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56: 782-789. PMID: 17148500
33. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK (2007) Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57: 373-380. PMID: 17513004
34. Hashiguchi Y, Tsuda H, Bandera CA, Nishimura S, Inoue T, Kawamura N, et al. (2006) Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer. Med Oncol 23: 205-212. PMID: 16720920
35. Chu H, Wang M, Shi D, Ma L, Zhang Z, Tong N, et al. (2011) Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies. PLoS One 6: e18108. doi: 10.1371/journal.pone.0018108 PMID: 21483822
36. Xu Q, He CY, Liu JW, Yuan Y (2013) Pre-miR-27a rs895819A/G polymorphisms in cancer: a metaanalysis. PLoS One 8: e65208. doi: 10.1371/journal.pone.0065208 PMID: 23762318
37. Alain K, Karrow NA, Thibault C, St-Pierre J, Lessard M, Bissonnette N (2009) Osteopontin: an early innate immune marker of Escherichia coli mastitis harbors genetic polymorphisms with possible links with resistance to mastitis. BMC Genomics 10: 444. doi: 10.1186/1471-2164-10-444 PMID: 19765294
38. Chu M, Yang P, Hu R, Hou S, Li F, Chen Y, et al. (2011) Elevated serum osteopontin levels and genetic polymorphisms of osteopontin are associated with Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 52: 7084-7089. doi: 10.1167/iovs.11-7539 PMID: 21810982
39. Ramchandani D, Weber GF (2013) An osteopontin promoter polymorphism is associated with aggressiveness in breast cancer. Oncol Rep 30: 1860-1868. doi: 10.3892/or.2013.2632 PMID: 23900428
40. Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M (2009) The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c- Myb transcription factor. Mol Carcinog 48: 14-23. doi: 10.1002/mc.20452 PMID: 18459127